| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8349f1c7debd07c1d268ce16cfa35e71 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-728
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y302-01017
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-04 |
| filingDate |
2018-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6dc16ea9f6326b1c1980560cd89fca0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d685475897e3978ee5aa8ac42b475a49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_700f6bb4fc4b82b042a09bb2de92f57a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_258d0eca1bd190ced09fb16798d5fa47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41af288802239bd56fc009a063475599
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95c3f96f023d7168ce36aebe29d70053 |
| publicationDate |
2020-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2018428270-A1 |
| titleOfInvention |
Novel artificial tears containing recombinant human lysozyme |
| abstract |
The present invention provides novel artificial tears containing a recombinant human lysozyme. The novel artificial tears comprise main components and an auxiliary material. The main components are a recombinant human lysozyme and a sodium hyaluronate, wherein the recombinant human lysozyme and the sodium hyaluronate are contained in an amount from 0.075% to 0.300 % and from 0.10% to 0.30% respectively in the total mass of the novel artificial tears. A drug for external use is prepared by combining the recombinant human lysozyme, the sodium hyaluronate and an excipient for treating light and moderate dry eye syndrome. |
| priorityDate |
2018-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |